title: [The rescue effect of RANKL on zoledronate induced acid inhibition of osteoclastogenesis and gene expression of NF-kappaB p50 and c-Jun].
abstract: In this study, the rescue effect of receptor activator for nuclear factor-kappaB ligand (RANKL) on zoledronate acid (ZOL) induced inhibition of osteoclastogenesis and gene expression of NF-kappaB p50 and c-Jun was investigated. Mice calvarial osteoblasts (OBs) were harvested and co-cultured with RAW264.7 cells and the cells were divided into 4 groups and received treatment with ZOL and RANKL, either single or combined. The formation of multi-nucleated osteoclast (OC) was examined and gene expression of NF-kappaB p50 and c-Jun was detected. Group B (ZOL) showed least multi-nucleated OC and resorption lacunae among the 4 groups (P < 0.05 or P < 0.01) and it was followed by group C (ZOL+RANKL). Group D (RANKL) showed highest OC and resorption lacunae while it was similar to Group A (control) (P > 0.05). Gene expression of NF-kappaB p50 and c-Jun was the lowest in group B (P < 0.05 or P < 0.01) among the four groups and was significantly increased in group C when compared with group B (P < 0.05). Group A and D showed highest gene expression and they were similar to each other (P > 0.05). This study suggest that RANKL might partly rescue ZOL induced inhibition of osteoclastogenesis, and the effect of RANKL and ZOL on osteoclastogenesis may be mediated by NF-kappaB p50 and c-Jun.
authors.forename: Chunfeng
authors.initials: C
authors.lastname: Xu
authors.forename: Peng
authors.initials: P
authors.lastname: Li
authors.forename: Shiyu
authors.initials: S
authors.lastname: Ding
authors.forename: Ren
authors.initials: R
authors.lastname: Li
authors.forename: Mengchun
authors.initials: M
authors.lastname: Qi
authors.forename: Jinyuan
authors.initials: J
authors.lastname: Li
mesh_terms: D000818:Animals; D001862:Bone Resorption / Q000188:drug therapy*; D002460:Cell Line; D004164:Diphosphonates / Q000494:pharmacology*; D015870:Gene Expression; D007093:Imidazoles / Q000494:pharmacology*; D051379:Mice; D052002:NF-kappa B p50 Subunit / Q000378:metabolism*; D010006:Osteoblasts / Q000187:drug effects*; D010010:Osteoclasts / Q000187:drug effects; D016755:Proto-Oncogene Proteins c-jun / Q000378:metabolism*; D053245:RANK Ligand / Q000494:pharmacology*; D000077211:Zoledronic Acid
chemical_list: D004164:Diphosphonates; D007093:Imidazoles; D052002:NF-kappa B p50 Subunit; D016755:Proto-Oncogene Proteins c-jun; D053245:RANK Ligand; D000077211:Zoledronic Acid